This IRB-exempt study utilized unembalmed female human cadavers. Sacrohysteropexy was performed on 6 cadavers, by affixing polypropylene mesh posteriorly on the uterus/ vagina and anchoring it to the anterior longitudinal ligament overlying the S1 sacral vertebrae. A 9/16 to 3/4-inch diameter metal washer was placed above the midline uterine fundus and attached to a 6 inch long, 8/32 diameter bolt that was threaded through a small opening created at the uterine fundus, down the cervical canal, and out the vagina. The vaginal end of the bolt was fastened to a waxed surgical filament oriented parallel to the table and over a fixed pulley at the table's end. Successive weights of 0.5 to 4.0 kg (in 0.5 kg intervals) were added to provide increasing loads on the uterine fundus, and the distances traversed by the fundus were recorded. The same process was repeated after completion of a total hysterectomy (with vaginal cuff closure) and subsequent sacrocolpopexy with posterior mesh placement. Data were analyzed using ANOVA for within group comparisons. The mean distances traversed for each weight for the two procedures were compared using Student's t tests (Sigma Plot version 13.0), with P 0.05 considered statistically significant. RESULTS: The mean age of the cadavers was 75.3 years. Average BMI was 26.6 kg/m2. All specimens were white. Average distances (AE standard deviation) in cm pulled with 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 kg of traction against the uterine fundus after sacrohysteropexy were 0.7
52 Treatment of ashermans syndrome with an intrauterine amniograft to provide a "scaffold" platform for endometrial cell regeneration G. Collins, S. Thakore, B. Patel, J. Liu University Hospitals Case Medical Center, Cleveland, OH OBJECTIVES: To determine if placing an AmnioGraft at the time of hysteroscopic treatment for Ashermans syndrome will promote regeneration of the endometrium. MATERIALS AND METHODS: This study was conducted on women with the diagnosis of severe Ashermans syndrome, a thin endometrial stripe, and a desire for future fertility. The AmnioGraft model was adapted from the ophthalmology literature, as it has been successfully used as a biologic ocular transplantation graft. On presentation to the fertility clinic, patients were counseled on the potential benefits of the biologic membrane, AmnioGraft, as it is designed to prevent scaring, reduce inflammation, and promote wound healing. The women then underwent operative hysteroscopy, lysis of intrauterine synechiae under ultrasound guidance, and curettage. A 3.5 x 3.5 cm AmnioGraft was wrapped around a Cook intrauterine balloon stent and inserted into the uterus. The stent was maintained for two weeks, and the patient received antibiotics and high dose estrogen therapy during this time period. RESULTS: Seven women received the AmnioGraft between the years 2011 and 2014. Five of the seven women had amenorrhea prior to the surgery (ranging from 1.5-8 months of amenorrhea), and all of the women achieved menses post-operatively. The average change in endometrial thickness of the pre to post-operative endometrial stripe was an increase of about 2.7 mm. Two of the seven women achieved pregnancy. The first patient had a di/di twin gestation after a cycle of in-vitro fertilization. The second patient had a spontaneous chemical pregnancy with a subsequent spontaneous singleton gestation. Three patients attempted IVF cycles and did not achieve a pregnancy; one patient has frozen embryos but has not undergone embryo transfer; and one patient decided to proceed with using a gestational carrier. CONCLUSION: The AmnioGraft may provide an alternative treatment option for patients with Ashermans syndrome who desire future menses and pregnancy. Future larger randomized studies need to be performed to confirm this result.
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